)
James Lynch
CEO
DNA Nanobots
A 38-year BioPharma Executive (Novartis, Pfizer, Mallinckrodt, Reliant, Savient, Rockwell Medical) with a successful track record of infusing focus and pace into startups. Finance/fundraising experience, as well as operational experience in all areas of drug development including clinical, regulatory, legal, manufacturing, BD&L/Corp, global project mgt, etc. Career highlights include a Founding member of a Specialty Pharma; raised $135M; grew to 1,080 employees/$341 M net sales; sold to GSK ($1.65B). Most recently, completed $4.1 M raise to conduct a first-in-human GBM cancer trial; transitioned from a pre-clinical to a clinical-stage company increasing valuation by $30M.
Sessions
-
24-Jun-2026Theater 3DNA Nanobots
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}